Zafgen, Inc. (ZFGN) Expected to Announce Earnings of -$0.59 Per Share
Wall Street brokerages expect that Zafgen, Inc. (NASDAQ:ZFGN) will announce earnings per share of ($0.59) for the current quarter, Zacks reports. Zero analysts have issued estimates for Zafgen’s earnings. Zafgen posted earnings per share of ($0.38) during the same quarter last year, which indicates a negative year-over-year growth rate of 55.3%. The company is expected to announce its next quarterly earnings report on Thursday, March 8th.
According to Zacks, analysts expect that Zafgen will report full-year earnings of ($2.02) per share for the current year. For the next fiscal year, analysts anticipate that the company will post earnings of ($1.35) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Zafgen.
Zafgen (NASDAQ:ZFGN) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.12.
A number of analysts have issued reports on ZFGN shares. Zacks Investment Research raised Zafgen from a “hold” rating to a “buy” rating and set a $3.75 target price for the company in a research note on Saturday, August 12th. ValuEngine upgraded Zafgen from a “strong sell” rating to a “sell” rating in a report on Monday, October 16th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $6.63.
In related news, Director Frances K. Heller acquired 10,000 shares of the firm’s stock in a transaction dated Friday, October 13th. The stock was acquired at an average price of $3.90 per share, for a total transaction of $39,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 21.20% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in ZFGN. Algert Global LLC purchased a new position in shares of Zafgen in the 2nd quarter valued at about $123,000. Parametric Portfolio Associates LLC raised its position in shares of Zafgen by 55.8% during the 1st quarter. Parametric Portfolio Associates LLC now owns 28,832 shares of the biopharmaceutical company’s stock worth $134,000 after acquiring an additional 10,327 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Zafgen during the 2nd quarter worth about $259,000. LMR Partners LLP acquired a new stake in shares of Zafgen during the 2nd quarter worth about $299,000. Finally, Acadian Asset Management LLC acquired a new stake in shares of Zafgen during the 2nd quarter worth about $304,000. Institutional investors and hedge funds own 48.57% of the company’s stock.
Shares of Zafgen (NASDAQ ZFGN) traded down $0.07 on Friday, hitting $3.65. The company’s stock had a trading volume of 64,300 shares, compared to its average volume of 201,749. Zafgen has a twelve month low of $3.11 and a twelve month high of $5.46.
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.